Daratumumab Regimen Keeps 81% of Newly Diagnosed Transplant-Eligible Myeloma Patients Progression-Free at Six Years in PERSEUS Update
A PERSEUS trial update showed 81% of multiple myeloma patients receiving daratumumab plus standard therapy were progression-free at six years, compared to 56% with standard therapy alone. Overall survival was 85.9% with daratumumab and 78.6% without. The trial involved 709 patients under 70 eligible for stem cell transplants. Johnson & Johnson's Darzalex Faspro, the drug's under-the-skin form, is approved in the U.S. for induction and consolidation but not maintenance.
How this was made
The 30-second read
Why it matters
The data suggest a durable benefit that could expand the drug's usage and support JNJ's oncology revenue forecasts.
Market read
First‑time disclosure of strong long‑term efficacy for a major oncology drug, likely to influence JNJ stock and the broader myeloma treatment sector.
What to watch
Potential safety concerns and the need for longer follow‑up could temper enthusiasm.
Background
The PERSEUS trial evaluated daratumumab combined with VRd in transplant‑eligible newly diagnosed multiple myeloma patients, reporting 6‑year outcomes for the first time.
Ticker impact
Johnson & Johnson's Darzalex (daratumumab) showed 81% 6‑year progression‑free survival in the PERSEUS trial, a new clinical result first reported at the International Myeloma Society meeting.
likely upward pressure as the market prices in improved efficacy and potential sales uplift.
First disclosure of robust 6‑year PFS data for a key oncology drug; investors typically reward such breakthroughs.
Market effects
strengthens the outlook for the multiple myeloma treatment market and may benefit other CD38‑targeting agents.
European and Australian markets may see modest gains in biotech stocks citing the data.
global oncology investors may re‑evaluate pipelines that compete with daratumumab.
Counterpoint
Skeptics may point to the lack of peer‑reviewed publication and limited US label approval for maintenance therapy.
Key entities
- CompanyJohnson & Johnson
Manufacturer of Darzalex (daratumumab).
- OrganizationInternational Myeloma Society
Host of the conference where the data were presented.
